Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (1492)	10/20/1998 9:28:00 AM
From: Dr. John M. de Castro	Read Replies (3) \| Respond to of 2742

Making each other rich is the basis for a good working relationship. IMHO Bluestone was paid an outrageous fee for their services. I especially object to the percentage of the business going forward. "7% of the equity and research payments ($133,000 in aggregate fees) to BlueStone should the Company execute definitive agreements with PMC as BlueStone assisted Cistron by introducing the parties. Cistron also would be obligated to pay BlueStone 7% of any license fees or milestone payments PMC may make to Cistron should PMC enter into definitive agreements and exercise its option under such." (Source CIST 10K) I suspect that Genome securities will now get their due. When will stockholders get theirs? John de C